Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 12, 2010

miRagen to Assess RXi’s Technology Against miRNA Targets of Interest

  • RXi Pharmaceuticals and miRagen Therapeutics entered into a collaboration to evaluate RXi’s rxRNA™ technology against specific miRNA targets of interest to miRagen in the cardiac and neuromuscular disease areas. Each party will contribute its technology and resources to the collaboration to generate novel miRNA compounds.

    RXi says that its version of RNAi compounds, developed on the rxRNA platform, provide an alternative to siRNAs. These include rxRNAori™, rxRNAsolo™, and sd-rxRNA™ (self-delivering RNA), which are distinct from classic siRNAs.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »